Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A Phase 2 trial of crenezumab in cognitively unimpaired PSEN1 mutation carriers found no significant clinical benefit over 5-8 years, suggesting that robust amyloid plaque removal may be essential for disease modification in early-stage Alz
Researchers developed EEGSurvNet, a deep survival model that analyzes routine EEG to predict seizure risk over two years. Outperforming clinical models, it achieved an AUROC of 0.80 at two months and showed high efficacy in patients without
The international NEOS2 study validates a refined clinical score using five baseline variables to accurately predict short-term immunotherapy response, one-year functional status, and three-year return to work or school in patients with ant
Recent studies highlight the critical role of virus-specific T-cells in treating progressive multifocal leukoencephalopathy. Pre-existing T-cells predict superior responses to checkpoint inhibitors, while allogeneic T-cell transfer offers a
A secondary analysis of a randomized clinical trial reveals that parent-led enhanced developmental intervention, beginning in the NICU and spanning two years, significantly improves executive function domains—including attention, inhibition
A comprehensive Swedish study reveals that long-term exposure to particulate matter and nitrogen dioxide significantly increases the risk of Motor Neuron Disease and accelerates functional decline, even in regions with relatively low pollut
Longitudinal data from the Women’s Health Study reveal that elevated Lipoprotein(a) is a potent, independent predictor of myocardial infarction and ischemic stroke over three decades, suggesting a critical need for universal screening in pr
The NEOS2 score, an updated clinical tool, accurately predicts treatment response, one-year functional status, and three-year work/school resumption in anti-NMDAR encephalitis patients, offering clinicians a robust framework for early treat
A randomized trial demonstrates that a 50-fold smaller, closed-loop vagus nerve stimulation (CLV) system is safe and significantly improves upper limb function in chronic stroke patients, with functional gains doubling during extended home-
The CRIPTOFAST trial demonstrates that ultra-early implantation of internal loop recorders significantly increases silent atrial fibrillation detection in cryptogenic stroke patients, particularly those with subtle left atrial anomalies, of
The multicenter BRAIN-AF trial found that rivaroxaban did not prevent cognitive decline or stroke in patients with atrial fibrillation and low CHA2DS2-VASc scores. Despite significant cognitive deterioration observed across both groups, the
A post hoc analysis of the CHANCE-2 trial suggests that the clinical benefit of ticagrelor over clopidogrel for secondary stroke prevention in CYP2C19 loss-of-function carriers is significantly attenuated in patients with high insulin resis
A secondary analysis of the LOOP study demonstrates that continuous ECG screening with implantable loop recorders significantly reduces stroke and systemic embolism in individuals with high genetic risk for atrial fibrillation, while potent
A secondary analysis of the AcT trial demonstrates that high-risk plaque features—such as intraluminal thrombi and carotid webs—significantly increase stroke risk even in patients with less than 50% carotid stenosis, challenging traditional
A comprehensive subgroup analysis of the CATIS and CATIS-2 trials reveals that continuing or reinitiating antihypertensive medication immediately after an acute ischemic stroke does not significantly affect mortality or disability rates, pr
A randomized controlled trial demonstrates that 6-month atorvastatin treatment significantly reduces aneurysm wall enhancement and systemic inflammatory markers in patients with unruptured vertebrobasilar dissecting aneurysms, potentially o
A secondary analysis of the PRESTIGE-AF trial reveals that specific MRI markers, including cortical superficial siderosis and macrohemorrhages, are more potent predictors of recurrent intracerebral hemorrhage than hematoma location alone, o
The Phase II HiWalk trial demonstrates that a 43-hour high-intensity walking booster program is safe and feasible for chronic stroke survivors, yielding significant walking speed improvements for individuals who have already completed their
The TaCAS long-term follow-up study reveals that a simple, conversation-based intervention can sustain improvements in physical health and independence for up to six years post-stroke, highlighting the lasting impact of patient-centered mot
A multicenter randomized controlled trial demonstrates that drug-coated balloons significantly reduce 6-month restenosis and 1-year recurrent ischemic events compared to bare-metal stents in patients with symptomatic high-grade intracranial
Open language-specific specialty feeds and department pages.